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ABSTRACT
Objective Management of age- related macular 
degeneration (AMD) places a high demand on already 
constrained hospital- based eye services. This study 
aims to assess the safety and quality of follow- up within 
the community led by suitably trained non- medical 
practitioners for the management of quiescent neovascular 
AMD (QnAMD).
Methods/design This is a prospective, multisite, 
randomised clinical trial. 742 participants with QnAMD will 
be recruited and randomised to either continue hospital- 
based secondary care or to receive follow- up within a 
community setting. Participants in both groups will be 
monitored for disease reactivation over the course of 12 
months and referred for treatment as necessary. Outcomes 
measures will assess the non- inferiority of primary care 
follow- up accounting for accuracy of the identification of 
disease reactivation, patient loss to follow- up and accrued 
costs and the budget impact to the National Health 
Service.
Ethics and dissemination Research ethics approval was 
obtained from the London Bloomsbury Ethics Committee. 
The results of this study will be disseminated through 
academic peer- reviewed publications, conferences and 
collaborations with eye charities to insure the findings 
reach the appropriate patient populations.
Trial registration number NCT03893474.
BACKGROUND
Neovascular age- related macular degeneration 
(nAMD) is the most frequent cause of blind-
ness and accounts for 50% of all certifications 
of visual impairment in the UK.1 2 Current 
treatment involves intravitreal injections of 
drugs to inhibit vascular endothelial growth 
factor (anti- VEGF) to ameliorate the pathology 
behind nAMD, improving the morphological 
appearance of the retina and stabilising/
improving visual acuity. This treatment process 
means that the disease becomes quiescent and 
standard clinical practice includes long- term 
follow- up of patients with quiescent nAMD 
(QnAMD) to monitor for the return of active 
disease and the need for further treatment.
While regular clinical review is an effective 
management strategy, this method is stressful 
for patients with frequent hospital visits and 
long waits in crowded clinics and burden-
some for the National Health Service (NHS), 
requiring ophthalmologist availability on a 
regular basis within a service that is already 
severely constrained. Demand for these 
Strengths and limitations of this study
 ► The main strength of this study is its potential to 
demonstrate the safety and cost- effectiveness of a 
community- based model of care for patients with 
stable age- related macular degeneration.
 ► The assessed care pathway promotes decentrali-
sation of care out of the hospital environment and 
enables shared care with non- medical healthcare 
practitioners.
 ► The study involves a comprehensive economic and 
process evaluation and a training package allowing 
this care pathway to be quickly implemented within 
healthcare systems.
 ► This care pathway is designed for the UK health set-
ting and may not be immediately generalisable for 
worldwide health systems.
 ► However, interventions such as this are timely and 
relevant to the global trend towards decentralisation 
of healthcare.
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services are predicted to increase further due to an ageing 
population. As a result, reviews to optimise the current care 
pathways and improve patient management have been 
published outlining possible options, including virtual or 
combined clinics, faster referral processes and the use of 
trained non- medical healthcare professionals within the 
hospital setting.3–5
Following these calls for improved clinical services, in 
2016, the Effectiveness of Community versus Hospital Eye 
Service follow- up for patients with neovascular age- related 
macular degeneration with quiescent disease (ECHoES) 
trial was undertaken to examine the possibility of primary 
care optometrists managing patient follow- up, with the 
aim of developing a shared care pathway for monitoring 
QnAMD. This study showed that the ability of optome-
trists to detect reactivated nAMD is non- inferior to that of 
ophthalmologists,6 did not incur significantly higher costs7 
and could reduce demands on hospital resources.6 7
This study continues investigating the potential of a 
community- based, non- medical practitioner- led pathway 
for the management of QnAMD. We believe this is an 
important development in AMD care. If safe, integrated 
and quality assured community care can be developed, this 
should provide opportunities to make services more acces-
sible and convenient for patients while also easing pressure 
on hospital eye departments and potentially lowering costs. 
Assessing the clinical and cost- effectiveness of community- 
based primary care QnAMD follow- up, we will examine:
1. The safety of non- medical practitioner follow- up of 
QnAMD in the primary care setting compared with 
secondary care eye clinics in correctly classifying reac-
tivation due to nAMD (primary objective).
2. The efficiency (rate of over- referral) of primary care 
and secondary care QnAMD pathways against an en-
hanced reference standard.
3. The non- inferiority of non- medical practitioner follow- 
up of QnAMD in the primary care versus secondary 
care eye- clinics in correctly classifying reactivation due 
to nAMD.
4. The cost- effectiveness and budget impact of 
community- based primary care optometry QnAMD 
pathways against secondary care pathways.
METHODS
Study design
This is a prospective, randomised, multisite clinical trial 
testing the non- inferiority of primary care optometry 
follow- up of participants with QnAMD over 12 months. 
Participants with QnAMD will be randomised to continue 
secondary care within a hospital setting (control arm) or be 
monitored for disease reactivation in a community setting 
by non- medical healthcare practitioners (primary care 
optometrists; intervention arm).
In both trial groups, participants will be reviewed at 
4- weekly intervals to monitor for disease reactivation, as 
per routine clinical practice in QnAMD clinics (figure 1). 
Participants in the intervention arm who are determined 
to have ‘active’ or ‘suspicious’ (where the assessing optom-
etrist cannot determine with certainty whether the disease 
is active or inactive) disease classification will be referred to 
the hospital eye service for a confirmatory review of their 
disease and will discontinue participation in the study. Any 
participants with reactivated disease from either trial group 
will be referred for treatment and will discontinue partici-
pation in the study.
Trial phases
The study will involve three phases: (1) a development 
phase consisting of training for primary care optometrists 
using an in- house bespoke training package developed by 
City, University of London, in collaboration with the College 
of Optometrists, (2) an internal pilot phase assessing the 
feasibility of the recruitment plan, performing quality assur-
ance of the training package and a process evaluation with 
criteria for progression to the full trial and (3) the full trial. 
This pilot will only involve recruitment at a selection of the 
available locations (the first wave sites). The full trial will 
involve recruitment up to the final determined sample size, 
include an assessment of economic outcomes and incor-
porate a substudy undertaking a process evaluation of the 
community- based optometry follow- up (intervention arm).
Setting
This study will take place at a number of locations across 
the UK, including London (Moorfields Eye Hospital), 
Manchester, Bristol, Bradford, Leeds and York (first wave 
sites) with further locations joining part way through the 
study.
Recruitment will take place at hospital- based eye units 
within each city, which will also deliver the secondary care 
(control) arm of the study. Thirty- five primary care optom-
etry practices of a range of sizes and types (independent, 
small group and multiples) and geographical locations 
will be recruited to deliver the community- based primary 
care for the intervention arm of the study. This number of 
optometry sites has been selected within an expectation that 
each site will perform an average of one to three appoint-
ments per week (up to 144 per year), and the distribution 
of practice sizes/types/locations has been selected to allow 
judgements to be made about applicability of findings to 
the wider UK population.
Participants
Participants considered for recruitment will be those with 
nAMD currently undergoing treatment with antivascular 
endothelium growth factor injections whom have reached 
disease quiescence. For the purposes of this study, disease 
quiescence for nAMD will be defined as:
 ► For participants on monthly pro renata regimens, a 
period of at least 3 months during which treatment 
has not been required.
 ► For participants on treat and extend regimens, 
successful extension of retreatment interval to 12 
weeks and maintenance of this interval for one or 
more consecutive occasions.
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Patients with bilateral nAMD will be considered for the 
study if both eyes have reached disease quiescence. For 
each follow- up visit in either trial group, a classification 
will be made separately for each eye. ‘Active’ and ‘suspi-
cious’ classification in either of the participant’s eyes will 
trigger a referral to secondary care for review/treatment, 
and corresponding participants will discontinue study 
visits.
Eligibility criteria
The inclusion criteria for this study are the achievement of 
disease quiescence, aged 55 years or older, have provided 
informed consent and have the ability to perform study 
specific procedures.
Participants will be excluded if they have the following:
 ► Significant media opacities (cataract and vitreous 
opacities) that would not allow good quality fundus 
imaging.
 ► Diabetic retinopathy of severity worse than mild non- 
proliferative stage and with any degree of diabetic 
maculopathy.
 ► Or a history of other causes of choroidal neovasculari-
sation (myopic, angioid streaks, inflammatory, retinal 
dystrophies, secondary to central serous chorioretin-
opathy and idiopathic).
Randomisation and blinding
Randomisation will be performed by site staff using the 
web- based randomisation tool: Sealed Envelope ( www. 
sealedenvelope. com). Sealed Envelope provides a proven 
reliable and centralised randomisation system. The system 
will be custom designed to the trial requirements. The 
method of randomisation will be minimisation with a 
ratio of 1:1. The minimisation algorithm will stratify (mini-
mise) by centre and number of eyes eligible at baseline 
(unilateral or bilateral). This is performed with an 80% 
Figure 1 Flow chart of study design and participant follow- up. Numbers of patients assessed, excluded and lost to follow are 
estimated samples based on previous studies. *Due to the COVID-19 pandemic, the 4- weekly follow- up interval was changed 
to 8- weekly follow- up interval. AMD, age- related macular degeneration.
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probability of allocating to the trial arm that reduces the 
imbalance.
Patients will be randomised into the control arm or the 
intervention arm.
The only masking in this study will be the statisti-
cians and health economists so that the analyses can be 
performed masked to treatment.
Outcome measures
Primary outcome
The primary outcome measure for this study is the propor-
tion of participants who reactivate within 12 months of 
randomisation (determined by the reference standard) but 
who are not identified as having reactivated in each trial 
arm (termed false negatives).
Secondary outcomes
The following secondary outcome measures will also be 
examined:
1. The proportion of participants who do not reactivate 
within 12 months of randomisation (determined by 
the reference standard) but are incorrectly identified 
as having reactivated in each trial arm (termed false 
positives).
2. The proportion of over- referrals in the intervention 
arm (community- based primary care) in comparison 
with the reference standard, that is, when classification 
is ‘reactivated’ or ‘suspicious’ but disease is classified at 
the hospital visit to be ‘inactive’.
3. The proportion of participants in the intervention arm 
who are correctly classified as reactivations at the con-
firmation visit (termed true positives).
4. The mean change in visual acuity (measured with ha-
bitual correction and pinhole) between baseline and 
12 months postrandomisation in each trial group.
5. The proportion of ‘suspicious’ lesion classifications in 
the intervention arm.
6. The proportion of patient non- attendance and loss to 
follow- up in each trial group.
Economic outcomes
The principal economic outcome measure for this study is 
to examine the incremental cost per quality- adjusted life 
year (QALY) gained over the estimated patient lifetime 
estimated from an economic model informed by trial data. 
Additional economic outcomes include:
1. The use of health services and patient costs collected 
via study case report forms and participant completed 
questionnaires.
2. The costs of interventions and subsequent care to the 
NHS modelled over the estimated lifetime.
3. The budget impact to the NHS.
4. The modelled estimates of visual impairment and 
QALYs based on responses to the EQ- 5D- 5L.
Substudy: process evaluation of the intervention arm
The process evaluation in the internal pilot will determine 
how the implementation of the community- based QnAMD 
clinics can be improved and identify corresponding 
contextual factors that underpin how and why the clinics 
work. Six optometry practices operating the QnAMD clinics 
and six hospitals in the control arm will be recruited. A triad 
of data collection will be undertaken again at each prac-
tice/hospital: patient and staff interviews and observation 
of care delivery.
Qualitative interviews will be employed to learn whether 
the community- based QnAMD clinics are acceptable to 
participants. A total sample of 27–36 participants (three to 
four per clinic) will be selected from across the study and 
control arms depending on how quickly data saturation is 
reached. The sample will not be stratified per se; instead 
a purposive maximum variation sample will be selected to 
generate a broad range of views on whether and how the 
clinic is acceptable to participants. In other words, we will 
seek to recruit participants from a diverse range of back-
grounds, ethnic groups, employment, housing, income and 
geographical area.
Questions will be oriented to perceptions of what it 
meant in terms of time, travel, parking and quality of 
care to visit a community clinic or hospital for routine 
follow- up.
An independent researcher will also seek interviews with 
doctors and optometrists (12–18, two to three per clinic) 
involved with the study and the control arm. This approach 
will again aid differentiation between what is a common 
issue and that specific to the new clinic pathway. Open- 
ended questions will also focus on whether the right type of 
patient attends, issues concerning the practicalities in the 
organisation and management of the clinic and resourcing 
including IT and digital equipment.
To supplement the data on the patient and staff inter-
views, we will also carry out semistructured qualitative obser-
vation in practice by shadowing participants through their 
‘journey’ there. We will use framework analysis with the 
purpose of mapping connections or relationships between 
different themes and interpret the data charts to identify 
the acceptability of community- based QnAMD clinics.
Sample size calculation
The ECHOES study has shown that the rate of false 
negatives per lesion assessment when conducted by 
an ophthalmologist was 62/994, that is, 6.2% (95% CI 
of 4.8% to 7.9%).6 Over the course of 1 year, a patient 
will typically have lesions assessed on 12 occasions. The 
overall chance of being a false negative at any point 
during the 12 months of follow- up is estimated at 20% 
(determined by the summation of the probability of reac-
tivating and the probability of being a false negative and 
deducting the chance of being a false negative on repeat 
occasions, with figures estimated from Madhusudhana et 
al).8 This estimate requires adjustment for the fact that 
ECHOES figures were based on scenarios and vignettes 
and did not factor in additional patient information that 
may be available to the clinician, thus the false negative 
rate is expected to be lower than 20% in reality. The test 
of non- inferiority will be one sided at the 2.5% level. 
This approach is the conservative approach which is the 
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standard for regulatory approval of new pharmaceuti-
cals and many devices.9 While approval has been made 
on the basis of a non- inferiority design with a one- sided 
alpha of 5%, this is generally frowned on and thus we 
have adopted the more conservative approach. One of 
the major challenges in the design of a non- inferiority 
trial is the determination of the non- inferiority margin. 
This margin is the smallest difference between patient 
management approaches which, if true, would mean that 
management by non- medical professionals is declared 
inferior. We adopted a non- inferiority margin of 10%, 
the same as margin adopted by the ECHOES study and 
appraised by five peer reviewers, none of whom suggested 
it was too large. It has subsequently been published within 
the BMJ Open paper6 and attracted no criticism or referee 
comment about it being too high.
With an overall sample size in each group of 337, a two- 
group large- sample normal approximation test of propor-
tions with a one- sided 0.025 significance level will have 
90% power to reject the null hypothesis that the test and 
the standard are not equivalent (the difference in propor-
tions, π₁ − π₀, is 0.1 or farther from zero in the same 
direction) in favour of the alternative hypothesis that the 
proportions in the two groups are equivalent, assuming 
that the expected difference in proportions is 0 and the 
proportion in the standard group is 0.2.
Thus, data of the primary outcome would be required 
from 674 participants in total. Seven per cent loss to 
follow- up was observed in the first year of the IVAN study10 
on a patient population with nAMD. We adopted a more 
conservative estimate of 10% loss to follow- up, leading to 
an overall sample size of 742 participants. Of these, 72 
participants are expected to be recruited in the pilot trial, 
with the remainder recruited from the full trial. Sample 
size calculation was conducted using nQuery Advanced 
software V.8.1.2.0.
Data confidentiality
Patient consent will be completed by the hospital site 
responsible for patient care. This includes the comple-
tion of a written consent form (blank form provided in 
the online supplemental material), which will be filed at 
the relevant hospital site responsible for the patient and is 
the only document that has patient identifiable data. On 
patient consent, each patient is assigned a study ID, which 
is used to complete the case report forms used for data 
collection. This is the only way the patient is identified in 
the study.
No personal patient data are shared with the central 
study team, or the practices at point of consent and 
randomisation. All Optical Coherence Tomography 
(OCTs) uploaded onto the database are also anonymised 
manually to remove patient identifiable data.
Data management and monitoring
Data (images and case report forms) will be sent via 
secure teleophthalmology link on an electronic database 
hosted in the Reading Centre at Moorfields/UCL Insti-
tute of Ophthalmology Biomedical Research Centre.
Classification as active or inactive nAMD by the Reading 
Centre on the basis of optical coherence tomography 
and clinical vignettes (standardised pro forma with visual 
acuity, systemic and ocular history and patient symptoms 
completed for each case) will be performed to provide 
the enhanced reference standard used to assess the study 
outcome measures. Quality- assured processes of grading 
will be used in the Reading Centre based on double 
reading with adjudication by the Reading Centre lead. 
Grading by the Reading Centre will be masked to patient 
identifiers and the site of origin.
Missing data queries, range checks, logic checks and 
data quality checks of the electronic database will be 
performed on a monthly basis by the IT applications 
team at Moorfields. Data queries found will be sent to 
trial coordinators for clarification and confirmation. Data 
entries within the electronic database will compared for 
completion and accuracy with discrepancies checked 
against paper data forms.
No formal interim data analysis has been planned.
Quality assurance/safety control
A random sample of 20% pseudoanonymised cases for 
each community optometrist will be reviewed every month 
at the Moorfields Reading Centre with feedback sent to 
the respective clinical teams. Patterns in rates of vision 
threatening errors will be evaluated by a quality assurance 
panel (consisting of the Chief Investigator (CI), two clini-
cian coapplicants and a professor of optometry) who will 
introduce remedial measures if required (eg, enhanced 
training, pausing recruitment).
Trial oversight
The overall management structure of this study will consist 
of a Trial Management Group (TMG), Trial Steering 
Committee (TSC), Data Monitoring Committee (DMC) 
and a Quality Assurance Panel (QAP). The TMG will be 
responsible for the day- to- day running and management 
of the trial, meeting regularly to discuss trial progression 
and examine mitigating strategies in case of issues arising.
The TSC will ensure the overall integrity of the study, 
safeguarding the rights and well- being of the partici-
pants and ensuring that this trial is conducted to the 
rigorous standards set out as Good Clinical Practice. This 
role includes ensuring appropriate ethical approvals are 
obtained, monitoring trial progress, investigating any 
serious adverse events, reviewing proposals for project 
amendments and recommendations made by the DMC.
The DMC will monitor the trial data to ensure that the 
trial is being implemented in accordance with the highest 
standards of patient’s safety and ethical conduct. Through 
the trial, the DMC will monitor recruitment, protocol 
compliance, emerging external evidence, sample charac-
teristics and primary outcome measures, as well as make 
recommendations to the TSC, such as whether interim 
analysis is required.
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Patterns in rates of vision- threatening errors identified 
during the monthly quality assurance process performed 
at the Reading Centre will be evaluated by the QAP 
(consisting of the chief investigator, two clinician coappli-
cants and a professor of optometry) to introduce reme-
dial measures if required (eg, enhanced training and 
pausing recruitment).
Statistical analysis
The primary analysis will be conducted following an 
intention- to- treat principle where all randomised partici-
pants are analysed in their allocated group whether, or not, 
they receive their randomised management plan. All tests 
will be two sided and will be assessed at the 5% significance 
level unless otherwise specified. All CIs will be 95% and two 
sided. All statistical analysis will be performed using R (The 
R Foundation for Statistical Computing Platform).
Analysis of primary outcome
The primary outcome is whether, or not, a patient has a 
lesion classified as a false negative within 12 months. This 
classification rate will be compared between management 
groups using logistic regression adjusting for randomisation 
stratifiers (minimisation factors: treatment centre and later-
ality). This analysis will allow information from each time 
point to be used up to the point at which a patient reac-
tivates. Outcomes will be reported as adjusted ORs. While 
our primary analyses will group suspicious and quiescent, a 
sensitivity analysis will be conducted where suspicious will 
be grouped with reactivated.
Survival analysis will then be used (in a secondary anal-
ysis) to test whether the time to false negative classifica-
tion differs between the two trial arms.
Analysis of secondary outcome
The secondary outcome of the proportion of false positives 
in each trial arm within 12 months will be compared using 
logistic regression, adjusting for randomisation stratifiers 
(minimisation factors: treatment centre and laterality) as 
described for the primary outcome.
The proportion of over- referrals in the intervention arm 
(in comparison with the reference standard), as well as the 
proportion of participants correctly classified as having 
‘reactivated’ QnAMD at the confirmation hospital visit, will 
be reported with 95% CIs computed by the exact binomial 
method.
Mean change in visual acuity (between baseline and 12 
months) in each trial arm will be compared using logistic 
regression adjusting for randomisation stratifiers (minimi-
sation factors: treatment centre and laterality) as described 
for the primary outcome.
The proportion of ‘suspicious’ lesion classifications in the 
intervention arm will be reported with 95% CIs computed 
by the exact binomial method.
The proportion of patient non- attendance in each trial 
arm will be compared using logistic regression adjusting for 
randomisation stratifiers (minimisation factors: treatment 
centre and laterality) as described for the primary outcome. 
The percentage of participants experiencing adverse events 
in the two groups will be reported with 95% CIs in the 
same way. Loss to follow- up will be examined by study arm. 
Reasons for missingness may be important, and these will 
be investigated using logistic regression of covariates based 
on an indicator of missingness. An available case analysis 
will be reported along with an analysis using imputed data 
based on different possible scenarios.
Economic analysis
Costs and outcomes associated with either trial group will 
be collected over the 12- month follow- up period. The 
costs for this within trial evaluation will be derived from 
published reference costs and microcosting for the inter-
vention pathways. The use of secondary care and primary 
care optometry services will be collected from the study’s 
case report forms. Any additional costs will be measured 
using a bespoke resource allocation questionnaire, which 
will measure NHS costs, personal and social services costs 
and patient out of pocket costs. This questionnaire will be 
administered at baseline, 6- month time point and 12- month 
time point. Cost estimates will be derived from published 
NHS resources costs.11 12 The number of appointments or 
treatments will be multiplied by the unit costs. The cost 
of the intervention itself will be subject to a microcosting 
exercise, which include staff, equipment, administration 
and any other relevant costs for delivering the intervention. 
The costs of participant time and travel when accessing care 
will be informed by the results of a bespoke time and travel 
questionnaire completed at month 13. These data will be 
used to calculate an average journey cost for each different 
kind of care (eg, hospital appointment and optometry 
appointment), which will be multiplied by the number of 
each journeys taken.
Health- related quality of life will be measured by use 
of the EQ- 5D- 5L questionnaire. The EQ- 5D- 5L will be 
collected from participants at baseline, 6 and 12 months. 
The response to the EQ- 5D- 5L will be converted into scores 
using population tariffs.13 The results from the EQ- 5D- 5L 
will be used to produce utility values at baseline, 6 and 12 
months for each participant. This approach will be used to 
estimate the QALYs produced for each arm of the trial using 
the under the curve approach. The within trial analysis will 
focus on analysing the trial data such that it can be used to 
parametrise an economic evaluation model. Thus, we will 
explore how costs and health state utilities vary according 
to events that might occur, for example, referral, changes 
in treatments, cost to optometry practices, etc. We will also 
explore how these outcomes might vary by location of care, 
clustering by care provider and practitioner experience.
An economic model will assess the cost- effectiveness of 
the alternative management options. Costs and health 
consequences, measured in terms of QALYs, associated 
with a policy of initial community- based primary care or 
initial care in secondary care over the patient lifetime will 
be compared. The results of the model will be presented 
in terms of costs, QALYs and incremental cost per QALY 
gained. The model will be developed in accordance with the 
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National Institute of Clinical Excellence (NICE) reference 
case,14 and we will characterise participants treatment path-
ways and the impact of alternative strategies. At this stage, 
we anticipate that the model will take the form of either 
a microsimulation or a discrete event simulation. These 
types of model would be most appropriate model type for 
this decision problem as they allow the representation of a 
clinical situation where participants can move between care 
settings and experience deterioration in health over time, 
which would be appropriate given the nature of nAMD. 
The precise structure of the model will be developed during 
the project and will reflect the clinical decision question 
and the course of the condition. The data from the trial 
will be the main source of data for the economic model, 
but further data with which to model outcomes beyond 
the 12- month follow- up will be derived from the literature 
and other existing data sources following guidance for best 
practice.15 These data will include information on factors 
such as adverse events of missed deterioration of symptoms. 
The base case economic evaluation will be carried out from 
a UK NHS and personal and social services perspective to 
take into account healthcare costs and longer term social 
care costs. Both costs and QALYs will be discounted in the 
base case at 3.5%.14 A wider cost perspective will be taken in 
sensitivity analysis. Other deterministic sensitivity analyses 
will include the impact of different unit costs and changes 
in discount rates. In order to characterise the uncertainty 
in the data used to populate the model, probabilistic sensi-
tivity analysis will also be conducted. The results of this 
latter analysis will be presented as cost/QALY plots and 
cost- effectiveness acceptability curves.
A budget impact model will also be produced. This 
model will estimate the health service costs to the NHS 
of adopting the community- based primary care service 
and will follow best practice methods. The approach 
will model costs for hypothetical cohort representative 
of the coverage of standard secondary care provided for 
up to a 10- year time horizon. It will present net budget 
impact and impact by sector (primary care or secondary 
care). Following best practice methods,16 all costs will 
be presented in a base year, but no discounting will be 
performed. Both deterministic and probabilistic sensi-
tivity analysis will be presented.
Patient and public involvement (PPI)
An AMD- specific PPI group based at the Manchester 
Royal Eye Hospital has been involved in the study since 
its development. This group consists of contributors who 
have previously or are currently receiving care for AMD. 
Contributors meet at least once a year with provision for 
additional face- to- face or ‘virtual’ meetings when input 
is required for potential protocol amendments or issues 
arising during the course of the study. An end- of- study 
debrief is planned with all PPI contributors, which will 
include discussions of the prioritisation and dissemina-
tion of study results both to the public as well as relevant 
healthcare professionals.
Adjustments made because of COVID-19
Due to the COVID-19 pandemic, participant recruitment 
was suspended for 102 days between 26 March 2020 and 6 
July 2020. This suspension period affected 67 patients and 
caused 10 to withdraw from the trial.
As a result of the pandemic, two adjustments have been 
made to the trial protocol and formally approved via 
Health Research Authority (HRA).
First, the patient review period was reassessed by surveying 
first wave NHS sites and community- based primary care 
practices. It was recommended that the 4- weekly inter-
vals are changed to 8- weekly intervals as per routine clin-
ical practice in QnAMD clinics post- COVID-19 lockdown 
(March–May 2020).
Second, to minimise the number of hospital visits and 
aid patient recruitment during the COVID-19 pandemic, 
the protocol was amended to allow for verbal consent over 
the phone, as well as written consent provided in person at 
hospital appointments.
DISCUSSION
This study aims to assess the clinical effectiveness 
and cost- effectiveness of a community- based, non- 
medical practitioner- led pathway for the management 
of QnAMD. Recommendations for the development 
of community- based eye care services have been 
proposed in the Royal College of Ophthalmologists 
‘Way Forward’ report as one possible way of reducing 
demand for overstretched hospital- based services.5 In 
addition, the recent revision of NICE guidance on the 
management of AMD makes specific reference to the 
need for further research on service delivery models, 
with emphasis on allied health professional extended 
roles and community- based care.17 These recommen-
dations mean that this study is a timely and much 
needed investigation, which will offer a possible inte-
grated care pathway for the management of QnAMD.
The FENETRE trial is funded through a National 
Institute for Health Research Health Technology 
Assessment programme supporting research that is 
immediately useful to patients, clinical practice and 
policy/decision makers, comparing proposed ‘tech-
nologies’ with the current best alternative while exam-
ining the clinical and cost- effectiveness of the new 
intervention. As a result of this funding, this trial is 
structured to meet the criteria in a number of ways:
1. It compares community- based primary care to the cur-
rent best alternative: secondary care within a hospital 
setting.
2. It examines clinical, patient- derived and economic 
outcomes, demonstrating whether community- based 
primary care is both non- inferior to current practices 
and cost- effective.
3. It includes a substudy evaluating the community- based 
primary care pathway and how it impacts patients’ 
quality of life.
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4. It includes a development of a bespoke training pack-
age, developed in collaboration with the College of 
Optometrists.
If this study shows the non- inferior and cost–bene-
fits of community optometry follow- up of participants 
with QnAMD, we believe that the included aspects of 
this study design will allow immediate response to be 
implemented including further development of this 
care pathways across the NHS. Not only would this 
implementation lead to a reduction in the clinical 
burden on hospital services, but it can also help to 
standardise AMD treatment across the UK. Recent 
work has highlighted inequalities in the access to AMD 
treatment within the NHS with a ninefold difference 
in procedure rates between areas of high treatment 
use and low treatment use.18 This difference can lead 
to wide variation in the number of injections patients 
receive to treat their nAMD and addressing the high 
demand on AMD services may go some way to correct 
this inequality.
Measures such as moving to community- based 
primary care can also improve the patient experi-
ence. Patient involvement work in preparation for 
this study highlighted that people with QnAMD place 
great importance on receiving care closer to home, in 
a timely and convenient way, and are also keen on a 
community service, which allows a closer relationship 
to develop between the treating optometrist and the 
patient. This feedback was reminiscent of the perspec-
tives of health professionals and patients interviewed 
as part of the ECHoES trial,19 which emphasised that 
the current services does not fit the needs and pref-
erences of patients with nAMD who could be better 
served by an integrated care pathway. Alongside this 
work, a recent systematic review assessing adherence 
to nAMD treatment has shown that distance to treat-
ment centre and poor experiences within treatment 
centres are contributing factors to non- adherence,20 
suggesting that changes to the current service would 
improve the patient experience and improve treat-
ment outcomes.
In conclusion, this study aims to show the non- 
inferiority of community- based, non- medical practi-
tioner- led care for patients with QnAMD, allowing a 
new clinical pathway to be adopted by ophthalmology 
services that will reduce demand on hospital appoint-
ments, reduce the cost to the NHS and improve the 
patient experience.
ETHICS AND DISSEMINATION
This study will adhere to the UK Framework for Health 
and Social Care research. Prior to participations, all 
subjects provide informed consent and are informed 
in advance that they can withdraw from the study at 
any time without penalty. The study was approved by 
the London Bloomsbury Ethics committee.
Once the study is completed, data will be accessible 
by the FENETRE study groups for analysis and dissem-
ination. Results of any analyses will be presented at 
national and international conferences and published 
in peer- reviewed scientific journals. We will also 
engage with Eye Charities such as the Macular Society, 
which is already involved with the TSC for this project, 
and Fight for Sight in order to ensure all channels of 
communication to the wider patient population are 
used to disseminate the results of this research and 
ensure they are acknowledged, selected and intro-
duced for use in the health and care service.
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